menu
    • menu
    [{"orgOrder":0,"company":"Fundaci\u00f3 Eurecat","sponsor":"Silicium Laboratories S.L. | San Antonio Technologies S.L. | Catholic University of Murcia (UCAM) | Zaidin Experimental Station, Spanish Council for Scientific Research (CSIC) Agency","pharmaFlowCategory":"DU","therapeuticArea":"Undisclosed","country":"SPAIN","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Silicon Dioxide API","moa":"Macrophage receptor MARCO","graph1":"Undisclosed","graph2":"Undisclosed","graph3":"Fundaci\u00f3 Eurecat","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Fundaci\u00f3 Eurecat \/ Silicium Laboratories S.L. | San Antonio Technologies S.L. | Catholic University of Murcia (UCAM) | Zaidin Experimental Station, Spanish Council for Scientific Research (CSIC) Agency","highestDevelopmentStatusID":"1","companyTruncated":"Fundaci\u00f3 Eurecat \/ Silicium Laboratories S.L. | San Antonio Technologies S.L. | Catholic University of Murcia (UCAM) | Zaidin Experimental Station, Spanish Council for Scientific Research (CSIC) Agency"}]

    Find Clinical Drug Pipeline Developments & Deals for LUDOX(R) AM-30 colloidal silica

    Menu

    LUDOX(R) AM-30 colloidal silica

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Fundació Eurecat

                            Country arrow
                            OPRD
                            Not Confirmed

                            Fundació Eurecat

                            Country arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Silicon Dioxide API

                            Therapeutic Area : Undisclosed

                            Study Phase : Undisclosed

                            Sponsor : Silicium Laboratories S.L. | San Antonio Technologies S.L. | Catholic University of Murcia (UCAM) | Zaidin Experimental Station, Spanish Council for Scientific Research (CSIC) Agency

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effect of Three Silicon Based Food Supplements on the Urinary Excretion of Aluminum and Other Metals (SILIAL)

                            Details : Silica is a Other Small Molecule drug candidate, which is currently being evaluated in clinical studies for the treatment of undefined medical condition.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 11, 2021

                            Lead Product(s) : Silicon Dioxide API

                            Therapeutic Area : Undisclosed

                            Highest Development Status : Undisclosed

                            Sponsor : Silicium Laboratories S.L. | San Antonio Technologies S.L. | Catholic University of Murcia (UCAM) | Zaidin Experimental Station, Spanish Council for Scientific Research (CSIC) Agency

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            EMS

                            Brazil arrow
                            OPRD
                            Not Confirmed

                            EMS

                            Brazil arrow
                            OPRD
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Silicon Dioxide API

                            Therapeutic Area : Dermatology

                            Study Phase : Phase IV

                            Sponsor : Luxbiotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety of Neosil on Chronic Effluvium

                            Details : Neosil Complete (Neosil) is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Alopecia.

                            Product Name : Neosil Complete

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 06, 2018

                            Lead Product(s) : Silicon Dioxide API

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase IV

                            Sponsor : Luxbiotech

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth